BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation ...

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

BrainsWay’s SWIFT depression protocol consists of an acute phase of five treatment sessions (ten minutes each) per day for ...
BMJ Open

Adverse effects of non-invasive brain stimulation as a treatment for mental disorders: protocol for a systematic review and meta-analysis

Introduction Mental disorders affect nearly one billion people worldwide, posing major challenges to public health. While conventional treatments like psychotherapy and pharmacotherapy are effective ...
Nasdaq

BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens

BrainsWay Ltd. BWAY recently announced an expansion of insurance coverage for its Deep TMS therapy in adolescent depression. The update signals growing payer confidence in non-drug neurostimulation ...

BrainsWay Wins Optum Coverage Expansion for Adolescent Deep TMS Depression Therapy

Detailed price information for Brainsway Ltd ADR (BWAY-Q) from The Globe and Mail including charting and trades.
Argus Leader

Moment of Clarity Publishes New Insight on How Deep TMS Therapy Advances Mental Health Treatment

Moment of Clarity has published a new educational resource titled “How Deep TMS Therapy Works,” providing a comprehensive overview of transcranial magnetic stimulation (TMS) and its emerging role in ...